Spots Global Cancer Trial Database for Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Official Title: A Phase II Trial of Cetuximab (C225) as Therapy for Recurrent Non-Small Cell Lung Cancer (NSCLC)
Study ID: NCT00063388
Conditions
Interventions
Study Description
Brief Summary: Determine tumor response rate and time to disease progression, survival and safety in total populations.
Detailed Description: To determine the tumor response rate and time to disease progression, survival and safety in the EGFR-positive, EGFR-negative and total populations.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
ImClone Investigational Site, Aventura, Florida, United States
ImClone Investigational Site, Miami Beach, Florida, United States
ImClone Investigational Site, Chicago, Illinois, United States
ImClone Investigational Site, Indianapolis, Indiana, United States
ImClone Investigational Site, South Bend, Indiana, United States
ImClone Investigational Site, Boston, Massachusetts, United States
ImClone Investigational Site, Boston, Massachusetts, United States
ImClone Investigational Site, Saint Louis, Missouri, United States
Contact Details
Name: E-mail: ClinicalTrials@ ImClone.com
Affiliation: Eli Lilly and Company
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
